Reneuron Stem Cell Retinitis Pigmentosa

Rene a global leader in the development of cell based therapeutics is pleased to announce positive long term data from the ongoing phase 1 2a clinical trial of its hrpc stem cell therapy candidate in retinitis pigmentosa rp and plans to expand the ongoing study.

Reneuron stem cell retinitis pigmentosa. 2a clinical trial of its hrpc cell therapy candidate in retinitis pigmentosa. Cell based therapeutics developer reneuron group updated the market. From our ctx human neural stem cell line. Our primary objective is the development of novel stem cell therapies targeting areas of significant unmet or poorly met medical need.

Pre clinical studies carried out in disease models by the our academic collaborators have demonstrated that when transplanted into the retina our hrpc technology has the potential to preserve existing photoreceptors. About reneuron we are a leading clinical stage stem cell business. Our hrpc stem cell therapy candidate for rp benefits from orphan drug designation in both europe and the us. We have worked with world leading collaborators and academic institutions in the retinal disease field to successfully take our retinitis pigmentosa programme through pre clinical development.

Thu 10 september 2020 16 00 a a a. Reneuron upbeat on retinitis pigmentosa therapy development. Rp is a group of hereditary. Retinitis pigmentosa is a group of hereditary diseases of the eye that lead to progressive loss of vision due to cells in the retina becoming damaged and eventually dying.